Fatal amiodarone-induced hepatotoxicity: A case report and literature review

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 2, 2008, Pages 96-101

  Chan, A L F ^a,b   Hsieh, H J ^a   Hsieh, Y A ^b   Lin, S J ^b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adverse drug reaction; Amiodarone; Hepato toxicity; Intravenous; Polysorbate 80

Indexed keywords

ACETYLSALICYLIC ACID; AMINOTRANSFERASE; AMIODARONE; ANTIDIABETIC AGENT; INSULIN; ORAL ANTIDIABETIC AGENT; PENTOXIFYLLINE; VERAPAMIL;

ACUTE PYELONEPHRITIS; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CASE REPORT; DIABETES MELLITUS; DRUG WITHDRAWAL; FATALITY; FEMALE; HEART ATRIUM FIBRILLATION; HEPATIC COMA; HUMAN; HYPERTENSION; JAUNDICE; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; PROTHROMBIN TIME; SIDE EFFECT; UNCONSCIOUSNESS;

EID: 39049152332     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46096     Document Type: Article

References (37)

1. Breuer HW, Bossek W, Haferland C et al. Amiodarone-induced severe hepatitis mediated by immunological mechanisms. Int J Clin Pharmacol Ther. 1998; 36: 350-352.
2. Capron-Chivrac D, Reix N, Quenum C et al. Hepatopathie aigue due a l'amiodarone. Étude d'un cas et revue de la litterature. Gastroenterol Clin Biol 1985; 68: 535-539.
3. De Korwin JD. Hepatite aigue imputee a l'amiodarone. Gastroenterol Clin Biol. 1986; 10: 688-689.
4. Fogoros RN, Anderson K-P, Winkle RA et al. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent drug refractory arrhythmias. Circulation 1983; 68: 88-94.
5. Giannattasio F, Salvio A, Varriale M et al. Three cases of severe acute hepatitis after parenteral administration of amiodarone: the active ingredient is not the only agent responsible for hepatotoxicity. Ann Ital Med Int. 2002; 17: 180-184.
6. Gough WB, Zeiler RH, Barreca P et al. Hypotensive action of commercial intravenous amiodarone and polysorbate 80 in dogs. J Cardiovasc Pharmacol. 1982; 4: 375-380.
7. Iba-ba J, Tilea M, Balligand JL, Lefebvre C. Amiodarone liver toxicity about two cases and review of literature. La Revue de Medicine Interne 2004; 25: 386-389.
8. Johnston GD. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK (ed). Meyler's side effects of drugs. 14th ed. Amsterdam: Elsevier; 2000. p. 523-574.
9. Kalantzis N, Gabriel P, Mouzas JD et al. Acute amiodarone-induced hepatitis. Hepato-Gastroenterol. 1991; 38: 71-74.
10. Kaufmann P, Torok M, Hanni A, Roberts P et al. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology. 2005; 41: 925-935.
11. Klasko PK. Drugdex System (edition expires 18/2003). Greenwood Village, CO: Micromedex; 1974-2002.
12. Lewis JH, Ranard RC, Caruso A et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology. 1989; 9: 679-685.
13. Lim PK, Trewby PN, Storey GCA et al. Neuropathy and fatal hepatitis in a patient receiving amiodarone. Br Med J. 1984; 288: 1638-1639.
14. Lupon-Roses J, Simo-Canonge R, Lu-Cortez L et al. Probable early acute hepatitis with parenteral amiodarone. Clin Cardiol. 1986; 9: 223-229.
15. Mason JW. Amiodarone. N Engl J Med. 1987; 316: 455-465.
16. MacFadyen RJ, Palmer TJ, Hisamuddin K. Rapidly fatal acute amiodarone hepatitis occurring in the context of multiple organ failure. Int J Cardiol. 2003; 91: 245-247.
17. McGovern B, Garan H, Kelly E et al. Adverse reactions during treatment with amiodarone hydrochloride. Br Med J. 1983; 287: 175-180.
18. Mountfield RJ. Senepin S, Schleimer M et al. Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. Int J Pharm. 2000; 211: 89-92.
19. Munoz A, Karila P, Gallay P et al. A randomized hemodynamic comparison of intravenous amiodarone with and without Tween 80. Eur Heart J. 1988; 9: 142-148.
20. Platou ES, Refsum H. Acute electrophysiologic and blood pressure effects of amiodarone and its solvent in the dog. Acta Pharmacol Toxicol (Copenh). 1986; 58: 163-168.
21. Podrid PJ. Amiodarone: reevaluation of an old drug. Ann Intern Med. 1995; 122: 689-700.
22. Poucell S, Ireto J, Valencia-Mayoral P et al. Amiodarone associated with phospholipidosis and fibrosis of the liver. Light, immunohistochemical and electron microscopic studies. Gastroenterology. 1984; 86: 926-936.
23. Ratz Bravo AE, Drewe J et al. Hepatotoxicity during rapid intravenous loading with amiodarone: description of three cases and review of the literature. Crit Care Med. 2005; 33: 128-134.
24. Reuter HD. Vitamins. In: Beeley L (ed). Side effects of drugs. Annual. 1988; 12: 327-331.
25. Richer M, Robert S. Fatal hepatotoxicity following oral administration of amiodarone. The Annals of Pharmacotherapy. 1995; 29: 582-586.
26. Rigas B, Rosenfeld LE, Barwick KW et al. Amiodarone hepatotoxicity. A clinicopathological study of five patients. Ann Int Med. 1986; 104: 348-351.
27. Sarma JS, Pei H, Venkataraman K. Role of oxidative stress in amiodarone-induced toxicity. J Cardiovasc Pharmacol Ther. 1997; 2: 53-60.
28. Simon JB, Manley PN, Brien JF et al. Amiodarone hepatotoxicity simulating alcoholic liver disease. N Engl J Med. 1984; 311: 167-172.
29. Simon JP, Zannad F, Trechot P et al. Acute hepatitis after a loading dose of intravenous amiodarone. Cardiovasc Drugs Ther. 1990; 4: 1467-1468.
30. Somberg JC, Timar S, Bailin SJ et al. Amio-aqueous investigators. Lack of a hypotensive effect with rapid administration of a new aqueous formulation of intravenous amiodarone. Am J Cardiol. 2004; 93: 576-581.
31. Somberg JC, Timar S, Bailin SJ et al. Lack of a hypotensive effect with rapid administration of a new aqueous formulation of intravenous amiodarone. Am J Cardiol. 2004; 93: 576-581.
32. Tanya C, McCarthy P, Pollak T et al. Dysruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-α target gene activation. The Journal of Pharmacology and Experimental Therapeutics. 2004; 311: 864-873.
33. Tosetti C, Ongari M, Evangelisti A, Lolli R, Napoli A. Acute hepatotoxicity from amiodarone. Minerva Med. 1998; 86: 387-390.
34. Vereckei A, Blazovics A, Gyorgy I, Feher E et al. The role of free radicals in the pathogenesis of amiodarone toxicity. J Cardiovasc Electrophysiol. 1993; 4: 161-177.
35. Waxman HL, Groh WC, Marchlinski FE et al. Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiological elects in 51 patients. Am J Cardiol. 1982; 50: 1066-1014.
36. Yagupsky P, Gazala E, Sofer S, Maor E, Abarbanel J. Fatal hepatic failure and encephalopathy associated with amiodarone therapy. The Journal of Pediatrics. 1985; 107: 967-970.
37. van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs. 2001; 19: 125-141.